FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)

View source ↗

Summary

FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)

Snippet

SUPPL AP for BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE)